Low-Dose Abiraterone with a Low-Fat Diet in Metastatic Prostate Cancer
Published Date: October 14, 2025
Low-Dose Abiraterone with a Low-Fat Diet in Metastatic Prostate Cancer
Written by: Taylor Yasunaga, PharmD, BCOP, Andrew Ruplin, PharmD, Dane Fritzsche, PharmD, BCOP, & Heather Cheng, MD, PhD
Abiraterone is a cornerstone therapy in metastatic prostate cancer, but the standard dose can be financially out of reach and the “take it fasting” requirement creates real adherence challenges. This article explores a strategy some centers are using to ease both the cost and pill burden: lower-dose abiraterone taken with a low-fat meal, leveraging the well-known food effect on drug exposure.
Using a single-center case series from Fred Hutchinson Cancer Center, it walks through what happened when patients started low-dose abiraterone specifically because standard dosing was cost-prohibitive. Along the way, it gets into the part practices wrestle with most: dietary consistency. The piece shows why “low-fat” needs to be more than a vague instruction, what can go wrong when education is inconsistent, and how real-world monitoring and follow-up can make this approach safer and more reliable.
What’s Inside:
- The cost problem that pushed patients toward a lower-dose strategy in the first place
- Why “low-fat meal” is the whole strategy, and also the biggest risk point
- What the case series revealed about durability of response in a real clinic population
- The safety signal that showed up when diet guidance was incomplete
- How a simple, standardized food education plan could reduce variability and risk
Read the full article in Oncolytics Today for the case-series takeaways on low-dose abiraterone with a low-fat meal, including what worked, what created risk, and what patient education needs to look like for this approach.